Date: 2015-01-13
Type of information: Licensing agreement
Compound: chimeric antigen receptor (CAR) technology targeting multiple myeloma cells
Company: Cellectis (France) Ohio State University (USA - OH)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease: multiple myeloma
Details: * On January 13, 2015, Cellectis announced that it has entered into an exclusive license agreement with The Ohio State University, through the Ohio State Innovation Foundation, to develop and commercialize chimeric antigen receptor (CAR) technology targeting multiple myeloma cells. The CAR technology licensed to Cellectis is related to CS1, an antigen that is over-expressed in multiple myeloma cells. Cellectis intends to pursue the development of a CS1 CAR T-cell program for this targeted indication. Cellectis is currently developing three proprietary allogeneic CAR T-cell product candidates in the field of liquid tumors, targeting CD123 in acute myeloid leukemia, as well as CD38 and CS1 for multiple myeloma. Cellectis aims to file in 2015 an application for a Clinical Trial Authorization for its allogeneic UCART191 product candidate, which targets CD19 in acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Financial terms:
Latest news:
